MDxHealth SA

mdxhealth is a commercial-stage precision diagnostics company that provides non-invasive, clinically useful, and cost-effective urologic solutions to improve patient care. The company's main testing solutions include Confirm mdx for Prostate Cancer, Genomic Prostate Score (GPS mdx), and ExoDx Prostate Test (Exo mdx). These tests offer personalized DNA and RNA insights to physicians and patients dealing with urologic disease and treatment options. The molecular diagnostic technologies provide personalized genomic results to help tailor approaches, aiming to improve patient well-being and reduce the need for invasive and unnecessary treatments. On August 5, 2025, mdxhealth agreed with Bio-Techne Corporation to acquire Exosome Diagnostics, Inc., which included the Exo mdx test, its CLIA-certified clinical laboratory, and related assets. The acquisition was completed on September 15, 2025. After the acquisition, customers who used Select mdx for men at risk for prostate cancer were transitioned to the new Exo mdx test. Over 7,000 urologists have ordered more than 500,000 mdxhealth tests. The company brings its diagnostic solutions to market through proactive engagement, education, and market expansion targeting healthcare professionals and patients. Confirm mdx, GPS mdx, and Exo mdx are recognized in National Comprehensive Cancer Network (NCCN) guidelines, an alliance of 31 leading cancer centers in the United States, and are reimbursed by Medicare. The commercial team focuses on building relationships with major community urology centers, prioritizing those with significant patient volumes, and fostering connections with key physicians and practice groups.